🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

15 results for “Aprea” Clear

  1. APR-246 + azacitidine

    Aprea Therapeutics

    MDS

    phase 3 small molecule completed

    1 trial

  2. APR-246

    Aprea Therapeutics

    Acute Myeloid Leukemia or Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  3. APR-246

    Aprea Therapeutics

    Myelodysplastic Syndrome With Gene Mutation

    phase 2 small molecule active

    1 trial

  4. APR-246

    Aprea Therapeutics

    Melanoma

    phase 2 small molecule terminated

    1 trial

  5. APR-246

    Aprea Therapeutics

    Myelodysplastic Syndrome

    phase 2 small molecule completed

    1 trial

  6. APR-246

    Aprea Therapeutics

    Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

    phase 2 small molecule completed

    1 trial

  7. APR-246

    Aprea Therapeutics

    High-grade Serous Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  8. APR-246 (eprenetapopt) + Acalabrutinib in CLL

    Aprea Therapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  9. APR-246 (eprenetapopt) + Pembrolizumab

    Aprea Therapeutics

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  10. ATRN-119

    Aprea Therapeutics

    HPV Positive Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. ATRN-119

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  12. APR-1051

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  13. APR-246

    Aprea Therapeutics

    Hematologic Neoplasms

    phase 1 small molecule completed

    1 trial

  14. APR-246

    Aprea Therapeutics

    Myeloid Malignancy

    phase 1 small molecule completed

    1 trial

  15. APR-548 + Azacitidine

    Aprea Therapeutics

    MDS

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources